Advanced and Innovative Nano-Systems for Anticancer Targeted Drug Delivery
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The encapsulation of therapeutic agents into nano-based drug delivery system for cancer treatment has received considerable attention in recent years. Advancements in nanotechnology provide an opportunity for efficient delivery of anticancer drugs. The unique properties of nanoparticles not only allow cancer-specific drug delivery by inherent passive targeting phenomena and adopting active targeting strategies, but also improve the pharmacokinetics and bioavailability of the loaded drugs, leading to enhanced therapeutic efficacy and safety compared to conventional treatment modalities. Small molecule drugs are the most widely used anticancer agents at present, while biological macromolecules, such as therapeutic antibodies, peptides and genes, have gained increasing attention. Therefore, this review focuses on the recent achievements of novel nano-encapsulation in targeted drug delivery. A comprehensive introduction of intelligent delivery strategies based on various nanocarriers to encapsulate small molecule chemotherapeutic drugs and biological macromolecule drugs in cancer treatment will also be highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Hydrogel: Preparation, characterization, and applications: A review
Ahmed, E. M. (2015) · Journal of Advanced Research · doi:10.1016/j.jare.2013.07.006 · Cited by 5,800 · cited 1×
“Common materials to constitute NG include polyacrylic acid (PAA), polyacrylamides (PAM), pluronic, multi-carbohydrates, and other high molecular polymers containing hydrophilic functional groups, such as protein-polysaccharides, polyvinyl alcohol (PVA) and polyaminoacid [115].”
BackgroundTGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 1×
“In addition, previous studies have demonstrated TGF-β played a promoting role in tumor growth and malignant progression [137,138].”
ResultSkog, J., Würdinger, T., van Rijn, S., Meijer, D. H., Gainche, L., Curry, W. T., Carter, B. S., Krichevsky, A. M., & Breakefield, X. O. (2008) · Nature Cell Biology · doi:10.1038/ncb1800 · Cited by 5,001
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011) · Nature Cell Biology · doi:10.1038/ncb2210 · Cited by 2,741
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells
Ohno, S.-I., Takanashi, M., Sudo, K., Ueda, S., Ishikawa, A., Matsuyama, N., Fujita, K., Mizutani, T., Ohgi, T., Ochiya, T., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.180 · Cited by 1,666 · cited 2×
“used exosomes to deliver the let-7a to epidermal growth factor receptor (EGFR)-expressing breast cancer cells [42].”
BackgroundMethodNanoemulsion: Concepts, development and applications in drug delivery
Singh, Y., Meher, J. G., Raval, K., Khan, F. A., Chaurasia, M., Jain, N. K., & Chourasia, M. K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.008 · Cited by 1,358 · cited 1×
“Nanoemulsions are stabilized with emulsifiers which are amphiphilic so that they can decrease interfacial tension between two phases [128,129].”
BackgroundTherapeutic developments in pancreatic cancer: current and future perspectives
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0005-x · Cited by 1,170 · cited 1×
“The dense fibrotic stroma in pancreatic ductal adenocarcinoma (PDA) resists drug diffusion into the tumor and leads to an unsatisfactory prognosis [111].”
BackgroundBertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., Lim, J.-M., Karnik, R., Langer, R., & Farokhzad, O. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00600-w · Cited by 708 · cited 1×
“The modification of NPs with proteins is a powerful approach that can bring plenty of additional advantages to the NPs [147].”
BackgroundExosomes and Exosome-Inspired Vesicles for Targeted Drug Delivery
Antimisiaris, S. G., Mourtas, S., & Marazioti, A. (2018) · doi:10.20944/preprints201810.0507.v1 · Cited by 605
Wang, P., Wang, H., Huang, Q., Peng, C., Yao, L., Chen, H., Qiu, Z., Wu, Y., Wang, L., & Chen, W. (2019) · Theranostics · doi:10.7150/thno.30716 · Cited by 494
Turturici, G., Tinnirello, R., Sconzo, G., & Geraci, F. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00228.2013 · Cited by 483 · cited 1×
“Exosomes derived from mesenchymal stem cells (MSCs) and DCs possess excellent intrinsic therapeutic activity and are used more widely [158].”
BackgroundExosomes in cancer development and clinical applications
Tai, Y., Chen, K., Hsieh, J., & Shen, T. (2018) · Cancer Science · doi:10.1111/cas.13697 · Cited by 426
Li, J., Wang, J., Zhang, X., Xia, X., & Zhang, C. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.09.085 · Cited by 17 · cited 2×
“adopted micelles as an ideal drug delivery vehicle to solve the MEL inherent cardiopulmonary toxicity and realize precision drug delivery [20].”
BackgroundMethodSelf-citation
Cited by
Understanding ligand-protected noble metal nanoclusters at work
Matus, M. F., & Häkkinen, H. (2023) · Nature Reviews Materials · doi:10.1038/s41578-023-00537-1 · Cited by 356
Liu, J., Guo, L., Mi, Z., Liu, Z., Rong, P., & Zhou, W. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.030 · Cited by 40
Riaz, S., Ali, S., Summer, M., Akhtar, U., Noor, S., Haqqi, R., Farooq, M. A., & Sardar, I. (2025) · Annals of Biomedical Engineering · doi:10.1007/s10439-025-03712-3 · Cited by 38
Dietary phytochemicals targeting Nrf2 for chemoprevention in breast cancer
Wang, P., Long, F., Lin, H., & Wang, T. (2022) · Food & Function · doi:10.1039/d2fo00186a · Cited by 28
Metadata
- Authors
- Tang, L., Li, J., Zhao, Q., Pan, T., Zhong, H., & Wang, W.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-07-27
- Volume
- 13
- Issue
- 8
- Pages
- 1151
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W3185552296
- Cited by
- 139
- References
- 18
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.